Clinical Trial Update: A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 [Phase 3]

View source ↗

Summary

A Phase 3 trial of lumasiran in infants and young children with primary hyperoxaluria type 1 has completed and posted results in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria Type

Drugs mentioned

• Lumasiran (lumasiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1) | Phase 3 | Status: COMPLETED | Results posted: 2021-07-19